Kancera AB (publ) (KAN.ST)
SEK 1.25
(2.97%)
SEK 1.25
(2.97%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -64.88 Million SEK | -23.64% |
| 2022 | -52.48 Million SEK | -14.88% |
| 2021 | -45.68 Million SEK | 3.94% |
| 2020 | -47.55 Million SEK | -31.76% |
| 2019 | -36.09 Million SEK | 21.42% |
| 2018 | -45.93 Million SEK | 18.26% |
| 2017 | -56.19 Million SEK | -151.92% |
| 2016 | -22.3 Million SEK | -13.75% |
| 2015 | -19.61 Million SEK | -22.74% |
| 2014 | -15.97 Million SEK | -115.41% |
| 2013 | -7.41 Million SEK | 77.85% |
| 2012 | -33.48 Million SEK | -81.9% |
| 2011 | -18.41 Million SEK | -157.59% |
| 2010 | -7.14 Million SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -10.9 Million SEK | 15.87% |
| 2024 Q1 | -12.96 Million SEK | 29.82% |
| 2023 Q3 | -10.73 Million SEK | 40.99% |
| 2023 Q4 | -18.46 Million SEK | -72.07% |
| 2023 FY | -64.88 Million SEK | -23.64% |
| 2023 Q2 | -18.18 Million SEK | -3.94% |
| 2023 Q1 | -17.49 Million SEK | -24.89% |
| 2022 Q4 | -14.01 Million SEK | -28.51% |
| 2022 Q3 | -10.9 Million SEK | 29.94% |
| 2022 Q1 | -12 Million SEK | 7.3% |
| 2022 Q2 | -15.56 Million SEK | -29.6% |
| 2022 FY | -52.48 Million SEK | -14.88% |
| 2021 Q4 | -12.95 Million SEK | -17.78% |
| 2021 FY | -45.68 Million SEK | 3.94% |
| 2021 Q1 | -9.08 Million SEK | 28.57% |
| 2021 Q2 | -18.26 Million SEK | -100.99% |
| 2021 Q3 | -10.99 Million SEK | 39.77% |
| 2020 Q2 | -13.8 Million SEK | -18.26% |
| 2020 FY | -47.55 Million SEK | -31.76% |
| 2020 Q3 | -9.36 Million SEK | 32.11% |
| 2020 Q4 | -12.71 Million SEK | -35.75% |
| 2020 Q1 | -11.67 Million SEK | -52.35% |
| 2019 Q1 | -7.95 Million SEK | 34.13% |
| 2019 FY | -36.09 Million SEK | 21.42% |
| 2019 Q4 | -7.66 Million SEK | -0.56% |
| 2019 Q3 | -7.61 Million SEK | 40.78% |
| 2019 Q2 | -12.86 Million SEK | -61.66% |
| 2018 Q4 | -12.07 Million SEK | -12.45% |
| 2018 FY | -45.93 Million SEK | 18.26% |
| 2018 Q3 | -10.74 Million SEK | -1.14% |
| 2018 Q2 | -10.62 Million SEK | 14.84% |
| 2018 Q1 | -12.47 Million SEK | -3.53% |
| 2017 FY | -56.19 Million SEK | -151.92% |
| 2017 Q2 | -17.98 Million SEK | -86.11% |
| 2017 Q1 | -9.66 Million SEK | -50.11% |
| 2017 Q3 | -16.5 Million SEK | 8.26% |
| 2017 Q4 | -12.04 Million SEK | 26.99% |
| 2016 Q3 | -5.36 Million SEK | 2.1% |
| 2016 Q1 | -5.03 Million SEK | 14.24% |
| 2016 FY | -22.3 Million SEK | -13.75% |
| 2016 Q4 | -6.43 Million SEK | -20.11% |
| 2016 Q2 | -5.47 Million SEK | -8.74% |
| 2015 Q4 | -5.87 Million SEK | -71.77% |
| 2015 FY | -19.61 Million SEK | -22.74% |
| 2015 Q1 | -4.91 Million SEK | 2.54% |
| 2015 Q3 | -3.41 Million SEK | 36.76% |
| 2015 Q2 | -5.4 Million SEK | -9.9% |
| 2014 Q2 | -3.75 Million SEK | 10.09% |
| 2014 Q4 | -5.04 Million SEK | -67.75% |
| 2014 FY | -15.97 Million SEK | -115.41% |
| 2014 Q3 | -3 Million SEK | 19.83% |
| 2014 Q1 | -4.17 Million SEK | -98.9% |
| 2013 Q4 | -2.09 Million SEK | 23.37% |
| 2013 Q3 | -2.73 Million SEK | 16.37% |
| 2013 Q2 | -3.27 Million SEK | -574.49% |
| 2013 FY | -7.41 Million SEK | 77.85% |
| 2013 Q1 | 690 Thousand SEK | 106.43% |
| 2012 Q3 | -6.43 Million SEK | 24.62% |
| 2012 Q1 | -7.8 Million SEK | -55.42% |
| 2012 Q4 | -10.72 Million SEK | -66.81% |
| 2012 FY | -33.48 Million SEK | -81.9% |
| 2012 Q2 | -8.53 Million SEK | -9.33% |
| 2011 Q1 | 733 Thousand SEK | 113.07% |
| 2011 Q2 | -8.89 Million SEK | -1313.1% |
| 2011 Q3 | -5.23 Million SEK | 41.17% |
| 2011 Q4 | -5.02 Million SEK | 4.03% |
| 2011 FY | -18.41 Million SEK | -157.59% |
| 2010 Q4 | -5.6 Million SEK | -576.36% |
| 2010 FY | -7.14 Million SEK | 0.0% |
| 2010 Q3 | -829 Thousand SEK | -16.6% |
| 2010 Q2 | -711 Thousand SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Asarina Pharma AB (publ) | -12.82 Million SEK | -405.839% |
| Vicore Pharma Holding AB (publ) | -310.94 Million SEK | 79.131% |
| NextCell Pharma AB | -41.95 Million SEK | -54.646% |
| Elicera Therapeutics AB (publ) | -16.39 Million SEK | -295.713% |
| Xbrane Biopharma AB (publ) | -388.17 Million SEK | 83.283% |
| AcouSort AB (publ) | -17.08 Million SEK | -279.712% |
| OncoZenge AB (publ) | -15.9 Million SEK | -308.056% |
| Xintela AB (publ) | -54.08 Million SEK | -19.98% |
| Ziccum AB (publ) | -21.41 Million SEK | -203.05% |
| Active Biotech AB (publ) | -45.8 Million SEK | -41.679% |
| Alzinova AB (publ) | -16.48 Million SEK | -293.744% |
| Amniotics AB (publ) | -30.87 Million SEK | -110.201% |
| Alligator Bioscience AB (publ) | -248.58 Million SEK | 73.897% |
| BioArctic AB (publ) | 229.24 Million SEK | 128.305% |
| Calliditas Therapeutics AB (publ) | -466.18 Million SEK | 86.081% |
| Camurus AB (publ) | 431.44 Million SEK | 115.04% |
| Cantargia AB (publ) | -280.02 Million SEK | 76.828% |
| Scandinavian ChemoTech AB (publ) | -21.09 Million SEK | -207.662% |
| CombiGene AB (publ) | -35.66 Million SEK | -81.938% |
| Diamyd Medical AB (publ) | -151.85 Million SEK | 57.268% |
| Genovis AB (publ.) | 61.5 Million SEK | 205.511% |
| Guard Therapeutics International AB (publ) | -113.32 Million SEK | 42.74% |
| Mendus AB (publ) | -101.61 Million SEK | 36.145% |
| Isofol Medical AB (publ) | -37.07 Million SEK | -75.04% |
| Karolinska Development AB (publ) | 5.38 Million SEK | 1304.772% |
| LIDDS AB (publ) | -40.2 Million SEK | -61.391% |
| Lipum AB (publ) | -37.17 Million SEK | -74.536% |
| Lipigon Pharmaceuticals AB (publ) | -12.12 Million SEK | -435.035% |
| Magle Chemoswed Holding AB (publ) | 12.16 Million SEK | 633.232% |
| Modus Therapeutics Holding AB (publ) | -17.89 Million SEK | -262.569% |
| Saniona AB (publ) | -95.81 Million SEK | 32.273% |
| Simris Alg AB (publ) | -37.3 Million SEK | -73.942% |
| Xspray Pharma AB (publ) | -179.66 Million SEK | 63.884% |
| Intervacc AB (publ) | -102.85 Million SEK | 36.91% |
| Sprint Bioscience AB (publ) | -438 Thousand SEK | -14714.84% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -16.52 Million SEK | -292.719% |
| Corline Biomedical AB | -1.8 Million SEK | -3487.009% |
| IRLAB Therapeutics AB (publ) | -177.83 Million SEK | 63.513% |
| Bio-Works Technologies AB (publ) | -56.82 Million SEK | -14.199% |
| Aptahem AB (publ) | -11.11 Million SEK | -483.909% |
| Infant Bacterial Therapeutics AB (publ) | -123.06 Million SEK | 47.274% |
| Fluicell AB (publ) | -26.55 Million SEK | -144.366% |
| Biovica International AB (publ) | -124.82 Million SEK | 48.015% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | -53.682% |
| Abliva AB (publ) | -95.5 Million SEK | 32.06% |
| Egetis Therapeutics AB (publ) | -326.9 Million SEK | 80.15% |
| 2cureX AB (publ) | -32.51 Million SEK | -99.548% |
| I-Tech AB | 20.2 Million SEK | 421.185% |
| Hansa Biopharma AB (publ) | -831.72 Million SEK | 92.198% |
| Cyxone AB (publ) | -22.98 Million SEK | -182.261% |
| ExpreS2ion Biotech Holding AB (publ) | -91.4 Million SEK | 29.006% |
| Biosergen AB | -27.03 Million SEK | -140.001% |
| Nanologica AB (publ) | -75.15 Million SEK | 13.662% |
| SynAct Pharma AB | -215.81 Million SEK | 69.932% |
| Annexin Pharmaceuticals AB (publ) | -44.05 Million SEK | -47.294% |
| BioInvent International AB (publ) | -330.3 Million SEK | 80.355% |
| Stayble Therapeutics AB (publ) | -23.73 Million SEK | -173.367% |
| Oncopeptides AB (publ) | -249.11 Million SEK | 73.952% |
| Pila Pharma AB (publ) | -9.93 Million SEK | -553.464% |
| Ascelia Pharma AB (publ) | -109.28 Million SEK | 40.626% |
| Diagonal Bio AB (publ) | -11.67 Million SEK | -455.652% |